Premium
EFFECT OF CURCUMIN ON METABOLOMIC PROFILES IN PANCREATIC CANCER CELLS
Author(s) -
Parasramka Mansi Anand,
Zaheeruddin Shaistha Mohammed,
Gupta Smiti Vaid
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.a1121
Subject(s) - curcumin , metabolomics , pancreatic cancer , chemistry , cancer , cancer research , medicine , biochemistry , chromatography
Pancreatic cancer (PC) remains a major public health issue, accounting for ~ 30,000 deaths/year in the USA. Most patients when diagnosed have metastasized tumors, limiting therapeutic options. Thus early detection is imperative for a favorable prognosis. Curcumin, the major bioactive constituent in turmeric, has proven anti‐inflammatory, antioxidant, and anti carcinogenic activity in several cancer types. In this study, we evaluated changes in metabolomics profiles (MP), due to curcumin addition, for biomarkers of early detection of PC. For this, PC cells, BxPc‐3, (RPMI‐1640 media; 37°C; 5% CO 2 ) were treated with curcumin at 5, 10 and 15μmol/L for 6, 12, 18, 24, 48 and 72 hours. A dose dependent decrease with curcumin on cell survival was observed by the MTT (3‐[4,5‐dimethylthiazol‐2‐yl] 2,5‐diphenyltetrazolium bromide) assay. Whole cell extracts (10% TCA precipitation) were subjected to Proton Nuclear Magnetic Resonance (1HNMR) spectroscopy. The NMR spectra were processed and analyzed using Principal Component Analysis (PCA), an unsupervised multivariate analysis technique which helps to cluster spectra from similar samples while separating them from samples differing in their metabolite composition, reflecting changes in cell metabolism. The change in MP may serve as biomarker for early diagnosis and progression of pancreatic cancer.